Emris Pharma

Emris Pharma Overview

EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment. Its solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies. SDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 31, 2023 · www.calcalistech.com

growth-positive

"We can bring relief, improve quality of life, and ensure better compliance with treatment for cancer patients" | CTech

EMRIS Pharma has raised $422,000 to develop a novel small molecule therapy to prevent skin toxicities induced by EGFR inhibitors in cancer patients. The company aims to enhance the quality of life for cancer patients by proactively blocking the drug-receptor interaction that causes skin toxicity. The therapy targets the root cause of the toxicities and is expected to allow patients to maintain their daily lives without compromising their anti-cancer treatments. EMRIS Pharma has an entirely female executive team and plans to begin human trials within three years. The recent investment round of $422,000 was led by the Israel Innovation Authority and NGT Healthcare II. The companys innovative solution addresses a significant need in the market and has the potential to revolutionize cancer treatment.

Investment

Jun 8, 2023 · www.prnewswire.com

growth-positive

EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

EMRIS Pharma, a spin-off of Hadasit and Yissum, is pioneering novel small molecule-based topical compounds to treat skin toxicities caused by EGFRi in cancer patients. The companys first product aims to improve the quality of life and treatment compliance for patients experiencing papulopustular skin rash. EMRIS Pharma has licensed the technology from Hadasit and Yissum, with NGT Healthcare2 VC as the founding investor. The lead compound developed by EMRIS Pharma has shown initial success in blocking EGFRi monoclonal antibodies. The companys innovative approach has the potential to significantly benefit cancer patients and increase treatment compliance. The event described in the article is the spin-off of EMRIS Pharma and the development of their novel cancer treatment product.

PartnersInvestment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Wadi el-Haj St 13, Nazareth, Israel

Photos & Videos

No files yet

Emris Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info